News Hub | News Direct

TRON and Pundi X Collaborate to Boost Cryptocurrency Adoption with XPOS Integration

TRON DAO

Geneva, Switzerland / November 6, 2023 / - TRON, a globally recognized leader in the blockchain space, has taken a monumental step forward by announcing a strategic collaboration with Pundi X, a pioneer in blockchain-based point-of-sale (POS) solutions. Central to this collaboration is the integration of Pundi X's innovative XPOS platform with the TRON network, facilitated by the TronLink wallet. This integration sets the stage for TRON users to seamlessly transact and oversee their digital assets, enhancing the practicality and accessibility of cryptocurrency transactions. By aligning the robust TRON network with the capabilities of the XPOS device via the TronLink wallet, TRON emphasizes its commitment to fostering widespread cryptocurrency adoption in everyday retail transactions. The XPOS device, admired for its user-centric design and efficiency in processing cryptocurrency trades, will now be geared to support TRON's expansive ecosystem, including its native utility token, TRX, as well as a spectrum of TRC-20 tokens. In supported jurisdictions, this collaboration by TRON and Pundi X promises to bridge the gap between traditional commerce and digital currency, ensuring a seamless and enriching transactional experience for both merchants and consumers. Prominent Features of the Integration: - Streamlined Transactions: Users, through their TronLink wallets, can now execute crypto trades utilizing the XPOS device, making transactions effortless in a wide range of physical retail environments. - A Commitment to Security: Pundi X's innovative technology with the robust security of the TRON network ensures transactions are executed with paramount safety. Zac Cheah, CEO and Co-Founder at Pundi X expressed his enthusiasm, saying, "Integrating with TRON is a monumental stride towards rendering cryptocurrency dealings to be more streamlined and user-centric. With the XPOS registering a 47% surge in USDT transactions on the TRON network this quarter, our alliance is in perfect sync with our vision of making blockchain technology mainstream for cryptocurrency transactions." Echoing these sentiments, Ecosystem Lead at TRON DAO Dave Uhryniak stated: "Our collaboration with Pundi X is a pivotal move in heightening the practicality and versatility of cryptocurrency usage. Integrating the TRON network with the capabilities of the XPOS device through TronLink wallet solidifies our collective vision of championing the digital payments industry." The synergy between Pundi X and TRON is poised to reshape how consumers engage with cryptocurrencies in brick-and-mortar settings. This collaboration is a testament to the transformative power of blockchain technology, heralding an era of innovation and convenience in financial systems. Please note that TRON network tokens on Pundi XPOS devices and other Pundi products are geo-restricted and not available to U.S. persons for purchasing or selling. About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by H.E. Justin Sun, the TRON network has continued to deliver impressive achievements since MainNet launch in May 2018. July 2018 also marked the ecosystem integration of BitTorrent, a pioneer in decentralized Web3 services boasting over 100 million monthly active users. The TRON network has gained incredible traction in recent years. As of October 2023, it has over 192.59 million total user accounts on the blockchain, more than 6.62 billion total transactions, and over $17.84 billion in total value locked (TVL), as reported on TRONSCAN. In addition, TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin across the globe, overtaking USDT on Ethereum since April 2021. The TRON network completed full decentralization in December 2021 and is now a community-governed DAO. Most recently in October 2022, TRON was designated as the national blockchain for the Commonwealth of Dominica, which marks the first time a major public blockchain partnered with a sovereign nation to develop its national blockchain infrastructure. On top of the government’s endorsement to issue Dominica Coin (“DMC”), a blockchain-based fan token to help promote Dominica’s global fanfare, seven existing TRON-based tokens - TRX, BTT, NFT, JST, USDD, USDT, TUSD, have been granted statutory status as authorized digital currency and medium of exchange in the country. TRONNetwork | TRONDAO | Twitter | YouTube | Telegram | Discord | Reddit | GitHub | Medium | Forum Media Contact Hayward Wong press@tron.network About Pundi X Based in Singapore, Pundi X was founded in 2017 with the aim of harnessing the power of blockchain technology to make a more secure and inclusive world. Pundi X is a leading developer of blockchain-based point-of-sale solutions, committed to making blockchain technology accessible to mainstream users. The company's XPOS device has been widely recognized for its role in simplifying cryptocurrency transactions at physical retail locations. Pundi X has also been selected as one of the top 50 Innovative Fintech Startups in 2018 by KPMG and H2 Ventures, cool vendors in blockchain business by Gartner, and one of the top 10 fintech leaders by Singapore Fintech Association in 2019. For more information, please visit https://www.pundix.com. Media Contact press@pundix.com Contact Details Hayward Wong press@tron.network Company Website https://trondao.org/

November 06, 2023 12:19 PM Eastern Standard Time

Image

News Release

Google Bard Price Prediction: Where Do Shiba Inu, Everlodge, and Dogecoin Go From Here?

Total Media

We have used Google Bard, one of the leading AI chatbots to scan the crypto market for three tokens with good price potential. In this article, we shall look at Google Bard's price prediction for Shiba Inu, Dogecoin, and Everlodge in Q4 2023. Shiba Inu's (SHIB) Burn Rate Dropped in October Shiba Inu (SHIB) remains one of the top memecoin in the crypto space despite the bear market. The Shiba Inu community is currently working on developing a decentralized ecosystem. Reports from Shibburn showed that there was a significant decrease in the number of SHIB tokens burned in October. According to Shibburn, the Shiba Inu community destroyed almost 1.46 billion SHIB tokens in October. In actuality, the burn rate for tokens in October was 37.12% lower than in September. The drop in the burn rate may indicate that investors are becoming less confident in Shiba Inu’s. They aren't actively taking part in the SHIB token burn as a result. As a result, they are not actively participating in the SHIB token burn. According to Shiba Inu CoinMarketCap data, the Shiba Inu price lost the key $0.00000800 level in November. Still, Google Bard's Shiba Inu price prediction remains bearish. Google Bard has forecasted the price of Shiba Inu token to reach $0.00000887 in Q4 2023. Dogecoin (DOGE) Bearish Despite “DOGE Day” The price of Dogecoin (DOGE) has increased by 20% in the past 10 days amid the Uptober market rally. On November 2nd, the memecoin community celebrated 2023 "DOGE Day." This day represented the birthday of "Kabosu," the dog that inspired the original "doge" meme. Meanwhile, historical data trends showed that whale trading activity increased in 2022. The same thing happened in 2023 as whale transactions rose from 790 on October 24th to 1,090 on November 1st. Notably, the price of Dogecoin crypto skyrocketed 100% from $0.060 to $0.12 in 2022. If history repeats, Dogecoin USD could see more upward price movement in the coming days. Unfortunately, Dogecoin CoinMarketCap info showed Dogecoin cryptocurrency dropped 3.1% to $0.067463. As a result, Google Bard has predicted that the chances of a 100% rally are low. Everlodge Allows Investors to Pool Resources To Buy Real Estate Properties Cryptocurrencies like Shiba Inu and Dogecoin are quite popular in the crypto space. However, new underdogs like Everlodge's ELDG have caught investors' attention. Everlodge is preparing to launch a new feature that will change the way individuals purchase and sell real estate. Encouraging more individuals to invest in real estate is their primary objective. Because real estate investing required a large initial investment, many people were afraid to do so in the past. Fortunately, Everlodge has promised to solve this problem by using NFT fractionalization. This means you can buy shares in luxury houses as NFTs without having to buy the whole property. How can you do this? By simply pooling your resources with others. In addition, you can earn extra income when these NFTs are rented out or sold. Currently, ELDG is valued at $0.023, which is over a 100% increase from its starting price of $0.01. So you know, analysts have predicted a 3,000% increase before the end of 2023. So, get in and join the best crypto project before it is launched. For more information about the Everlodge (ELDG) Presale you can visit their website or join their community here. Contact Details Media Team media@everlodge.io

November 06, 2023 12:00 PM Eastern Standard Time

Minuteman Press Franchise Owner Nil Patel Talks Leaving Corporate World, Celebrates Grand Opening in Solon, Ohio

Minuteman Press International Inc

After working in corporate finance, Nil Patel was looking for a career change. He shares, “I previously graduated from the University of Cincinnati with a bachelor’s degree in finance. After 8 years in the corporate world, I realized it was not for me. I wanted to be part of a company that helps others and be somewhere I can feel gratitude from the work I do!” Nil found what he was looking for in June of 2023 when he purchased the Minuteman Press franchise in Solon, Ohio. He explains, “I chose Minuteman Press because I wanted to be a part of a small business that has potential to grow and help other business thrive around me. The training and support from Minuteman Press International has been great! My RVP Rich DeRosa in particular has been extremely helpful and professional.” In September of 2023, Nil celebrated his grand opening; Minuteman Press in Solon is located at 33528 Aurora Road, Solon, OH 44139. Nil shares, “The community of Solon is a diverse blue-collar town where people are proud of the work they do! Our grand opening was a huge success. It was put together by the Solon Chamber of Commerce and I received extra help from my girlfriend and parents to really bring it all together. I’m excited to continue to serve and be a contributing member of the Solon community.” A few months into owning the business, Nil is happy with his progress as a business owner. He says, “I explain to clients that Minuteman Press in Solon is a full-service design, print, and marketing center serving the entire business community from small businesses to Fortune 500 companies. Our client base and business have been steady and we are growing.” Nil adds, “High-demand products that can help other local businesses/organizations grow are business cards, banners, flyers, and promo products – pens, calendars, koozies, flash drives, etc.” When asked about the industry and what he enjoys the most thus far, Nil answers, “Printing remains vital today because physical and digital advertising are both continuing to grow and this trend is going to continue.” He concludes, “Clients are looking for a healthy mix of both and I love that I can grow my business while helping others grow as well.” Minuteman Press in Solon, Ohio is located at 33528 Aurora Road, Solon, OH 44139. For more information, visit their website: https://minuteman.com/us/locations/oh/solon Learn more about #1 rated Minuteman Press franchise opportunities and read Minuteman Press franchise reviews at https://minutemanpressfranchise.com Contact Details Minuteman Press International Chris Biscuiti +1 631-249-1370 cbiscuiti@mpihq.com Company Website https://minutemanpressfranchise.com

November 06, 2023 10:00 AM Eastern Standard Time

Image

News Release

Ethereum and Polygon NFTs Hit Minimum Monthly Sales In 2023 While Nugget Rush Attracts New Buyers

RoundHouse Media

Ethereum and Polygon NFTs Hit Minimum Monthly Sales In 2023 While NuggetRush Attracts New Buyers TL;DR Monthly sales for Ethereum (ETH) and Polygon (MATIC) NFTs on OpenSea have fallen consecutively in the past few months. NuggetRush (NUGX) prepares to launch a highly anticipated play-to-earn mining game that will allow swapping of NFTs for real gold. Despite recent market bullishness, NFT sales have declined further in the past few weeks. Ethereum and Polygon are some of the most affected networks. Now, market experts are trying to predict what effect this would have on ETH and MATIC. Elsewhere, NuggetRush (NUGX) is providing an immersive experience that perfectly meets the desires of mining enthusiasts. The platform offers several mining rewards that players can easily convert to real-world value. Yet, analysts wonder if NuggetRush is a good crypto to buy now. Let’s see what they think. >> Buy NuggetRush Now << OpenSea Records Annual Low of Ethereum and Polygon NFTs Ethereum (ETH) and Polygon (MATIC) are home to most NFTs available on the market. However, the bearishness of 2022 and 2023 has affected NFT sales on Ethereum (ETH) and Polygon (MATIC). OpenSea, one of the largest NFT marketplaces, recorded a sharp drop in monthly NFT sales from both networks. In January 2023, Ethereum (ETH) NFT sales reached $659 million. Yet by September, it had dropped by 51% to $74 million. Likewise, Polygon NFT sales in February were around $109.12 million. However, it had fallen to $4.5 million in September. Despite the falling NFT activity, Ethereum (ETH) and Polygon (MATIC) recorded improved market performance in October. ETH was trading at $1,663.63 on October 2. Yet, ETH rose by 8.7% to $1,810 by October 30. Likewise, MATIC was trading at $0.5685 on October 1. By October 30, MATIC rose by 14.3% to $0.649. Analysts say ETH and MATIC’s recent performance could be due to excitement over potential Bitcoin Spot ETF approval. Other analysts say new partnerships signed by Ethereum (ETH) and Polygon (MATIC) have led to short-term rallies for both projects. Ethereum has recorded rising network adoption due to the popularity of ETH staking. Likewise, Polygon’s (MATIC) zkEVM is gaining widespread adoption, thus increasing network activity. Analysts conclude that NFT activity might remain low until the year ends. However, Ethereum and Polygon’s network activity could keep rising. If that happens, ETH could rise by 17.1% to $2,120. Likewise, MATIC might rise by 42.2% to $0.923. NuggetRush (NUGX): Exploring a Miner’s Deepest Desires NuggetRush (NUGX) combines an exciting adventure and a way to reward and grow a community of like-minded individuals. The platform is building an ecosystem to welcome new and old miners alongside people who love adventurous play-to-earn games. In NuggetRush (NUGX), players must find and mine mineral resources. Players receive rewards with financial value. The game features a richly detailed virtual landscape with high mineral resource potential. It gives players experienced NFT characters who include skilled miners and business professionals. These NFT characters and machinery help players explore new territories and extract mineral assets. NuggetRush (NUGX) features an immersive gaming environment with realistic mechanics that keep players engaged. >> Buy NuggetRush Now << Moreover, the game offers high-earning potential that allows players to find valuable rewards regardless of location or skill level. To get the opportunity to win NuggetRush’s mining rewards, users must first purchase the NUGX token. NuggetRush (NUGX) is yet to launch and is still holding a blockchain ICO. NUGX is still in Stage 2 of its presale, trading at $0.012. Its value would soon grow in Stage 3 of its presale. When NUGX rises to $0.020, NuggetRush will launch. Analysts say NUGX’s growth prospects could make it one of the best new ICOs. Visit NuggetRush Presale Website Contact Details NuggetRush Team media@nuggetrush.io

November 06, 2023 10:00 AM Eastern Standard Time

News Release

BNB's Binance Launches Memecoin Staking Opportunity, Cardano Consolidates After Rally, InQubeta Aims for $1 in 2023

Web3 AI Media

The crypto landscape is buzzing with activity. Recently, Binance, the largest centralized exchange in the crypto space, announced a new staking opportunity for the community. The Binance Launchpool debuted Memecoin (MEME) staking opportunities for the holders of BNB, TUSD, and FDUSD. This provides an opportunity to earn, which has been met with excitement, unsurprisingly. In other news, Cardano (ADA) is in a consolidation phase after a period of rallying. Meanwhile, InQubeta (QUBE), one of the new ICOs (initial coin offerings), is aiming for $1 before the end of the year. In this article, we will cover the launch of Memecoin staking by Binance. In addition, we will explore the decline in the momentum of Cardano. Finally, we will delve into InQubeta’s potential, including why it is one of the altcoins to watch out for in the coming months. InQubeta (QUBE): The Road to $1 In contrast to Cardano and BNB, InQubeta (QUBE) is a new player in the crypto space. It is an innovative project on the initial coin offering list, popular for blending AI and blockchain technology, and has been stirring up interest. What is the significance of InQubeta’s convergence of AI and blockchain? It aims to transform the fundraising landscape of the AI sector by leveraging blockchain technology. To achieve its goal, it will become the first crowdfunding platform for AI startups through crypto, using its utility token, QUBE. This project is in the fourth stage of its presale phase and has managed to raise a whopping $4.3 million. Its current price is $0.0161, and analysts predict it will reach the $1 mark before mid 2024. This makes it arguably the best new crypto to invest in. If you wish to become an early adopter of this intriguing project, simply follow the link below. Visit InQubeta Presale Binance Launches Memecoin Staking The development that has taken a part of the crypto community by storm is the introduction of Memecoin (MEME) as a new staking opportunity. This token is currently featured on the Binance Launchpool staking platform. But what is Memecoin? It is the native utility token of Memeland, a Web3 venture studio. Binance plans to distribute 2% of the total supply of Memecoin, over 1.3 billion, to users on the Launchpool. Holders of BNB and the stablecoins TUSD and FDUSD can earn Memecoin by staking their holdings. Notably, this exercise will be held between October 28 and November 26. So, if you haven’t started staking, now is the best time to do so. Cardano (ADA) is in a Consolidation Phase What is Cardano (ADA)? At this point, it requires little to no introduction. After all, it is one of the top altcoins in the market and a top ten cryptocurrency. Simply put, it is a proof-of-stake (PoS) blockchain platform that allows the development of decentralized applications (dApps) and smart contracts. Therefore, Cardano is integral to the blockchain landscape. Although Cardano has real-world applications and a solid foundation, it is currently in a consolidation phase. Nevertheless, it is worth noting that before this, ADA was on the upside. So, what will be its next move? Well, it is uncertain for now. Nevertheless, Cardano is expected to rally in the future, making it a good crypto to buy. Conclusion The unveiling of Memecoin as a new staking opportunity has been met with enthusiasm within the crypto community. In addition to this, Cardano is consolidating, while InQubeta has its sights set on the $1 mark. InQubeta’s fundamentals and investor interest in it will both play an important role in its rise. Visit InQubeta Presale Join The InQubeta Communities Contact Details Solomon marketing@inqubeta.ai

November 06, 2023 09:15 AM Eastern Standard Time

How IN8bio Is Working To Reach Its Goal Of “Cancer Zero” – Making Cancer A Thing of The Past

Benzinga

By Ted Stavetski, Benzinga IN8bio Inc. (NASDAQ: INAB) is a clinical-stage biotechnology company tackling one of society’s most pressing issues: cancer. Specifically, the company is focused on using the immune system to eliminate residual tumors, and currently has two clinical programs focused on leukemia and on glioblastoma, the deadliest type of brain cancer. IN8bio is pioneering a new approach using the immune system to tackle the deficiencies that plague most current cancer treatments. Alpha-beta T cell-based chimeric antigen receptor, or CAR-T therapies have shown remarkable results against some leukemias and myelomas. However, many of these CAR-T treatments have faced challenges against more difficult-to-treat leukemias, such as acute myeloid leukemia (AML) and solid tumor cancers. These cancers can be highly heterogenous, making them difficult to kill since they are often intertwined in healthy tissues, leading to unintentional toxicities and adverse events. In some cases, patients have even died. Fortunately, IN8bio may have found the solution to this problem. What Is “Cancer Zero?” IN8bio set out on a mission that it calls “Cancer Zero”, which co-founder and CEO William Ho describes as “the goal of pursuing the safe eradication of all tumor cells in patients fighting cancer.” In other words, the company aims to eliminate all cancer cells without destroying healthy cells. To achieve this, the company has developed advanced technologies using a specific subset of immune cells, or lymphocytes called gamma-delta T cells, in its DeltEx platform. Gamma-delta T cells are white blood cells whose job in the body is to be a first-responder and to determine safe and not-safe. They kill invading or dangerous cells and can call in reinforcements by recruiting and activating other immune cells. It was IN8bio’s co-founder, Dr. Lawrence Lamb, a clinical immunologist on a cancer ward treating patients with aggressive leukemias in the 1990s, who made the first observation that gamma-delta T cells are linked to greater survival in cancer patients. He spent the next 25 years figuring out how to expand, genetically engineer and manufacture gamma-delta T cells at scale and into a cancer therapy. In 2016, IN8bio was launched to take these gamma-delta T cell technologies into the clinic and today, Dr. Lamb is IN8bio’s Chief Scientific Officer. He leads a team of scientists and researchers dedicated to achieving the company’s mission of Cancer Zero. IN8bio’s DeltEx platform uses gamma-delta T cells that it believes are potentially safer and more effective at killing cancer cells than other therapies currently in development. The company has the capability to utilize autologous (from the patient), allogeneic (from a donor or “off-the-shelf”) and induced pluripotent stem cell (iPSC)-derived gamma-delta T cells. These cells can be expanded, activated and genetically engineered outside of the body to increase their numbers and to enhance their hunting and killing abilities. In one platform unique to IN8bio, its drug resistant immunotherapy (DRI) technology enhances gamma-delta T cells by genetically engineering them to be chemotherapy resistant. Chemotherapies have been a mainstay of front-line cancer therapy since World War II. While effective at shrinking a tumor and prolonging survival, they also kill white blood cells. As a result, microscopic residual tumors that are resistant to therapy often remain and result in relapse because of the weakened immune system. IN8bio’s DRI approach allows the simultaneous combination of chemotherapy with an immune therapy that may create synergies that allow the DRI gamma-delta T cells to recognize and eliminate the residual tumor cells while leaving healthy tissues alone. By targeting compartments of residual tumor cells, IN8bio’s DRI approach may achieve deeper tumor responses that can prolong survival. The company has already protected the DRI technology behind this process with issued patents around the world. IN8bio: Drugs In Clinical Development IN8bio has three therapies that are in varying stages of clinical development: INB-400: A phase 2 multi-center clinical trial for the treatment of newly diagnosed glioblastoma, or GBM ( NCT05664243 ). This trial has recently initiated enrollment at leading brain tumor centers across the United States following clearance of a company-sponsored investigational new drug application, or IND, by the U.S. Food and Drug Administration, or FDA. This program received Orphan Drug Designation (ODD) from the FDA in the spring of 2023 for targeting a significant unmet medical need, which offers potential incentives such as 7-year market exclusivity. INB-200: A phase 1 clinical trial at the University of Alabama at Birmingham using autologous, genetically modified DRI gamma-delta T cells for the treatment for newly diagnosed glioblastoma (UAB - NCT04165941 ). This program was one of only four central nervous system (CNS) cancer programs to have received an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the largest world-wide yearly gathering of cancer clinicians and researchers. At that time, the company released initial phase 1 data showing that 100% of treated patients have exceeded expected median progression-free survival. An additional clinical update is expected in November 2023 at the Society for Neuro-Oncology Annual Meeting (SNO), and long-term follow-up data is expected to be presented at medical meetings in the first half of 2024. INB-100: A phase 1 trial for the treatment of patients with high-risk leukemias undergoing haploidentical stem cell transplantation, or HSCT ( NCT03533816 ). The company presented a clinical update at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting in April 2023 that demonstrated 100% of evaluable patients (n=7) treated with INB-100 remained alive, progression-free and in durable complete remission (CR) as of April 21, 2023. Patients included high-risk AML patients and a patient with acute lymphoblastic leukemia (ALL) who had failed four prior lines of therapy, including CAR-T. All evaluable patients remained alive as of the last assessment and one patient had survived for three years. IN8bio has completed primary enrollment of the phase 1 clinical trial, with updated results expected at the American Society of Hematology (ASH) Annual meeting in December 2023. Topline long term follow ups are expected in 2024. To further its research, IN8bio recently opened a new 10,000-square-foot research & development (R&D) facility in Birmingham, Alabama. This state-of-the-art facility not only bolsters the company’s ability to advance its groundbreaking pipeline of gamma-delta T cell therapies, but also further taps into the advanced cancer research at the UAB, and other prominent institutes. Additionally, the company holds a total of 19 granted U.S. and international patents with many more still pending approval. This will help IN8bio protect its innovative new therapies from competitors as they proceed through clinical trials towards future commercialization. Cancer Immunotherapy Market IN8bio is tackling a large market. Grand View Research estimates that the global cancer immunotherapy market was worth approximately $115 billion in 2022 and is expected to grow at a compound annual growth rate of 8.7% from 2023 to 2030. Diving deeper, the American Cancer Society estimates that there will be 59,610 new cases of leukemia (and 23,710 deaths) in 2023, and the National Brain Tumor Society estimates that there were 13,400 new cases of glioblastoma in 2022. Despite being a lesser-known disease, awareness of glioblastoma is growing quickly. This is mainly due to the unfortunate, high-profile deaths of the President’s son, Beau Biden, and former U.S. Senator John McCain. One Step Closer Towards Cancer Zero IN8bio’s portfolio of cell therapies has the potential to offer a better treatment option for patients suffering from difficult to treat solid and liquid tumors such as AML and glioblastoma. The company’s primary advantage is its patent-protected platform gamma-delta T cell technologies, which it believes may allow it to better target cancer cells, getting deeper responses without hurting the patient’s healthy cells. The biotechnology company has had its foot on the gas pedal in recent years, boasting the following achievements: Two programs in phase 1, and enrollment has been initiated in its corporate-sponsored phase 2 trial at multiple sites across the U.S. A portfolio of preclinical programs in development including: iPSC derived gamma-delta T cells platform. iPSCs represent a significant step toward next generation approaches of cellular manufacturing for true allogeneic and potentially ‘off-the-shelf’ cellular therapies. INB-300, which focuses on addressing various solid and liquid tumors using a dedicated gamma-delta non-signaling CAR-T, or nsCAR, construct. These nsCAR constructs are designed specifically for the biology of gamma-delta T cells and allow IN8bio to potentially target tumor tissues while leaving healthy tissue alone. This could potentially create safer and more potent therapies. 19 granted patents for its technology. A brand new state-of-the-art R&D facility. $17 million in cash on hand, as of June 30, 2023, to help fund its operations and drug development. While the company is currently unprofitable – posting a net loss of $7.7 million for the three months ended June 30, 2023 – this is largely expected for biotechnology companies in the clinical development stage as they work to develop new drugs. However, IN8bio’s approach to business appears to be quite different in the biotechnology industry. The company reports it has been able to advance its clinical and preclinical programs by being extremely efficient with the capital raised, searching for innovative ways to advance their preclinical and clinical programs. Whereas IN8bio has successfully advanced multiple programs into phase 1 and 2 clinical trials while only having spent $76.5 million through 2Q23, a number of competing cell therapy companies have spent far more while showing similar, or less progress. Co-founder and CEO, William Ho has over 22 years of combined experience managing biotechnology companies, healthcare finance and investing, while co-founder and CSO, Lawrence Lamb has been in cellular therapy for three decades. They and the rest of the management team have the experience and know-how to effectively execute, manufacture, develop and advance the company’s growing portfolio of cancer therapies. With any luck, IN8bio will be able to achieve their mission of Cancer Zero, making cancer a thing of the past. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 06, 2023 09:00 AM Eastern Standard Time

Where Is Your Doctor Investing? Chances Are It Could Be DLP Capital – A Deep Dive Into The Returns Offered By The Firm’s Housing-Focused Funds

Benzinga

By Austin DeNoce, Benzinga Physicians, after years of intensive training and practice, are known for their rigorous and methodical approach when making decisions that impact their patients' health. This same attention to detail can often extend to their financial investments, and many are curious about where successful doctors invest their money. Treating patients, like investing, requires intelligence and patience. Among the myriad of investment choices available, DLP Capital emerges as an interesting choice due to its comparable ethos reflected in its broader vision of positively impacting society, and doctors seem to have taken notice – the company reports doctors have invested over $260 million in DLP Capital’s housing-focused funds. A Glimpse Into DLP Capital's Portfolio Since it was founded in 2006, DLP Capital has solidified its position in the investment landscape, earning a spot on the Inc. 5000 Fastest-Growing Companies list and retaining it for 11 consecutive years. The firm manages assets valued at over $5 billion, drawing support from a diverse pool of more than 2,600 investors. Owning and overseeing over 18,000 housing units, several of their funds have met or even surpassed their targeted returns. Through their varied endeavors, DLP Capital claims to have positively impacted more than 838,000 lives. Historical Returns: A Snapshot DLP Lending Fund: With a target annual return of 9-10%, this fund managed a 12.71% annual return as of September 30, 2023. As a private REIT emphasizing rental housing in high ownership-cost areas, it offers investors liquidity, a rigorous borrower vetting process and a 90-day redemption period without long-term constraints. Prioritizing investor returns, all preferred payouts are dispensed before any management fees, and invested capital retains a top-tier position, ensuring payment precedence over common equity participants. DLP Building Communities Fund: With an ambitious target of 11-13%, this fund achieved an annual return of 12.81% by the end of 2022. Designed as an evergreen private real estate fund, it focuses on developing new rental communities for attainable housing while providing a measure of protection against stock market volatility, consistent asset valuation for growth and flexible redemption options. All returns are prioritized to investors before any management fee is levied, ensuring their capital retains a preferred, high-priority position in all deals. DLP Preferred Credit Fund: This fund achieved a return of 10.52% in Q2 for 2023 on its 10-11% annual target, emphasizing insulation against rising interest rates and ensuring liquidity. By rigorously vetting borrowers and prioritizing loans to seasoned real estate sponsors, the fund ensures investors enjoy a preferred payment position and monthly returns before management fees, aligning the interests of DLP with its investors. Focusing on debt and preferred credit investments in the Sun Belt, its intent is to make a dent in America's affordable housing crisis, ensuring that rentals are attainable for working families. DLP Housing Fund: Perhaps the most eye-catching of the lot, DLP reports this fund saw an annual return of 27.04% by September 30, 2023, much higher than its annual target of 10-11%. By investing equity in multifamily rental communities (including manufactured housing and RV), the fund emphasizes both renter affordability and investor returns. The fund operates as an open-ended, private real estate venture focusing on long-term assets to yield enhanced returns. Investors not only benefit from tax advantages like depreciation offsets and 1031 tax-deferred exchanges, but they also enjoy flexible annual redemptions and a preferred position, guaranteeing payment priority over common equity investors. With returns like this, DLP may seem like a natural choice for many, but doctors are being attracted to DLP Capital for multiple reasons. The Attraction Of Passive Income One of the primary draws for busy professionals – such as those in the medical field – is the concept of passive income. They can enjoy the fruits of their investments without the daily demands of active engagement. DLP Capital's offerings, especially with its history of consistent returns, specifically aim to satisfy this demand for passive income – and doctors seem to find them particularly appealing. Impact Investing: Partnering With Doctors To Do Good Professionals like doctors frequently align their investment choices with societal benefits. Given the intrinsic desire among many in the medical profession to contribute positively to society, there's potential interest in DLP Capital, primarily due to its initiatives in affordable housing. Specifically, the DLP Housing Fund focuses on rental housing aimed at those with incomes near the area median. Likewise, the DLP Preferred Credit Fund and the DLP Building Communities Fund incorporate rental affordability into their strategies. Consequently, these funds combine financial objectives with addressing a relevant societal challenge. Exceeding Expectations DLP Capital has maintained a consistent investment record. Since its founding in 2006, there have been no reported capital losses for investors. Such reliable performance, alongside the size of potential returns, are important considerations for those evaluating investment options. Some of DLP Capital's funds have also achieved returns beyond their initial targets, reflecting reasonable success for some of its investment strategies. At the very least, their performance suggests a capacity to meet and occasionally exceed market expectations, though past performance is not a guarantee of future performance. Don Wenner, the CEO of DLP Capital, has played a significant role in the firm's direction. With over 16,000 real estate transactions amounting to more than $4 billion since 2006, his experience is extensive. Leveraging his experience, DLP's overarching mission includes both profit generation and broader goals to positively influence millions of lives. DLP Capital's Prognosis DLP Capital has positioned itself within the investment space by emphasizing passive income, societal impact and consistent returns – and successful professionals like doctors seem to be paying attention, with over a quarter of a billion invested by the medical community. The firm offers a comprehensive approach that integrates passive revenue streams, initiatives in affordable housing and a track record that reflects its strategy and performance over time. All returns aside, DLP Capital's alignment with affordable housing initiatives echoes the ethos of many in the medical profession and could be attractive to others, especially those seeking to yield a positive societal impact through their investments. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 06, 2023 09:00 AM Eastern Standard Time

Bing Ventures Presents Ethereum 2030, Devconnect’s Premier Event

Bing Ventures Limited

Bing Ventures, a Singapore-based pioneering venture capital firm backing early projects in Web3 and Blockchain, is joining hands with leading crypto exchange BingX to present Ethereum 2030: Unraveling Tomorrow’s Innovations, a premier event during Devconnect 2023 on Wednesday, November 15, 2023, at 2:00 pm GMT+3 in Istanbul. Ethereum 2030 will bring together industry heavyweights, visionaries, and trendsetters for a half-day of engaging keynote speeches, in-depth panel discussions, valuable networking opportunities, and audience engagement – all focused on inspiring and nurturing entrepreneurs for a new era of innovation. The event will be held at Sofitel Istanbul Taksim, which sits in the heart of the city, with unique views of Taksim Square and the mesmerizing Bosphorus and has the capacity to welcome up to 1,000 attendees. The agenda covers various topics, including decentralized finance, Ethereum scalability, Web3 security, and the crypto landscape in Turkey. Featured speakers include: Yajin (Andy) Zhou, CEO of Blocksec Azeem Khan, Head of Impact at Gitcoin Jack He, Co-founder at Aspecta Bertuğ Oymak, Co-Founder and CEO of Utilify Dougie DeLuca, Investor at Figment Capital Fatih Taşdemir, Co-Founder of Koin Bülteni Volkan KORKMAZ, CEO and Co-Founder at Altcointurk Luca (Moss) Mossini, BD at Avantgarde & Enzyme Finance Seraphim Czecker, Head of Taking Risk Varuni Trivedi, Editor in Chief at Voice of Crypto Anıl Öz, Chief Technology Officer at DATS Project Arif Kalem, Brand Ambassador of Turkey at BingX Özge ERDEMİR, Web3 Advisor, Business Developer Sima Baktas, Web3 Attorney at GlobalB Law / Co-Founder of CryptoFemale Daria Krasnova, Managing Editor at BeInCrypto Wayne Wu, Partner of Bing Ventures highlighted the purpose of the conference, saying: “As the largest and most established decentralized programmable blockchain in the world, Ethereum has been at the forefront of ground-breaking trends. We’re thrilled to convene a diverse gathering of international and local industry participants to share knowledge, exchange ideas, and inspire one another to push the boundaries of Ethereum.” The event is supported by event partners including Bankless Ventures, Figment Capital, Gitcoin, OneKey, Cedro Finance, Aspecta, Alchemy Pay, CryptoFemale, and Altcointurk, as well as media partners including Cointelegraph, BeinCrypto, Voice of Crypto, Bitcoin Insider, Unlock Blockchain, PANews, Coinpedia, Koinbülteni, and Muhabbit. To learn more and register for the free event, please visit: https://Ethereum2030.eventbrite.sg About Bing Ventures Bing Ventures is a pioneering venture capital firm that backs startups and entrepreneurs driving the next wave of Web3 and blockchain innovations. Its team of crypto veterans and natives collectively brings decades of experience in investing in, incubating, developing, and marketing Web 3.0 projects. With a sector-agnostic, value-investing approach, it now has a portfolio spanning infrastructure, DeFi, GameFi, DAOs, Web3, and more. Contact Details Bing Ventures Jenny Liu +86 159 2140 1005 jenny@bing-ventures.com Company Website https://www.bing-ventures.com/

November 06, 2023 09:00 AM Eastern Standard Time

Image

News Release

Former Analyst at Ark Invest Bullish on Solana - Where Next For Dogecoin and Everlodge?

Total Media

Chris Burniske, a former analyst at Ark Invest, is bullish on the future of Solana (SOL), and investors are diversifying with the cryptocurrency. In addition, Dogecoin (DOGE) and Everlodge (ELDG) are also getting significant attention following their recent price movements. Today, we will jump into the price performance for each crypto to see how far they can spike. Summary Solana is projected to climb in value to $29.22 by the end of 2023 Dogecoin can climb as high as $0.098 by the end of Q4 Everlodge to rise in value by 2,500% at launch Chris Burniske Is Bullish on the Future of Solana (SOL) Solana (SOL) has recently been in the spotlight as it achieved a significant price upswing. With its recent milestone in mind, analysts are bullish on its future. Chris Burniske, a former analyst at Ark Invest, for example, observed how there are several factors that indicate a bullish performance for Solana. The coin's recent price against Ethereum is the foremost indicator. It achieved the 0.02 mark against ETH, which indicates a strong market acceptance and confidence in its future. This breakthrough suggests a potential trajectory towards its next threshold. The Solana trading volume jumped 28% during the past 24 hours. In addition, its value increased from $30.13 to $36.78. In the past two weeks, Solana is up 51.5%. According to the Solana price prediction, it will experience a price upswing to $29.22 by the end of 2023. Dogecoin (DOGE) to See a Rapid Upswing Dogecoin (DOGE) recently saw a price upswing, and analysts are bullish on its future. During the previous week, the price of the Dogecoin crypto moved from $0.065 to $0.074, making $0.080 its next major resistance point. However, the Dogecoin market cap is at $9,799,553,676, and it has remained the 10th largest crypto on the market. According to the current Dogecoin price prediction, it can reach as high as $0.098 by the end of 2023. While this is a bullish outlook, Dogecoin was not the only altcoin to grab attention. Everlodge (ELDG) Can Rise in Value by 2,500% at Launch Everlodge (ELDG) is an upcoming marketplace that will enable anyone to access luxurious properties at a fraction of the cost. In addition, it will eliminate key issues that are plaguing the market. These include high costs of entry, lack of accessibility, and lack of transparency. The properties will get minted as NFTs and, as a result, will enable anyone the opportunity to jump into making investments through the usage of blockchain technology. These NFTs will get split into numerous smaller parts, where investors can begin buying a fraction starting at $100. This means that without needing a lot of upfront capital, anyone can build a diversified portfolio through which they can get passive income, assuming they are rental properties. ELDG can also be staked for passive income, and it is also used for governance. This native token is now at Stage 6 of the presale offered at $0.023. At launch, the crypto can surge as high as 2,500%. For more information about the Everlodge (ELDG) Presale you can visit their website or join their community here. Contact Details Media Team media@everlodge.io

November 03, 2023 11:00 AM Eastern Daylight Time